An Oxfordshire university student is among those set to receive a "transformative" gene-therapy treatment on the NHS for ...

Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...

New data from a Phase 1b clinical trial testing Fulcrum's pociredir for sickle cell disease are expected by the middle and ...

The withdrawals included a handful of notable market exits such as Pfizer’s Oxbryta in September 2024 and Takeda’s Exkivity in October 2023. Among the controversial approvals was another Sarepta asset ...

What is Oxbryta for sickle cell disease? Oxbryta (voxelotor), which is now withdrawn from the market due to safety concerns, was an oral small molecule conditionally approved in the U.S. for children ...

Be among those who shape the future with knowledge. Uncover exclusive stories that captivate your mind and heart with our FREE 14-day subscription trial. Dive into a world of inspiration, learning, ...

Oxbryta (voxelotor) is a brand-name drug that’s prescribed for sickle cell disease in adults and certain children. As with other drugs, Oxbryta can cause side effects, such as headache ...

Plant cell biology is the study of all aspects of plant cells. It is particularly concerned with structure, growth, division, signalling, differentiation and death of plant cells. The study used ...

Takeaway: The suit is the latest in a string of suits filed following the recall of Oxbryta, a drug used to treat sickle-cell disease. Lawyers: Marcus J. Bradley and Kiley Lynn Grombacher of ...

In 2022, Pfizer made a $5.4 billion investment in Global Blood Therapeutics and its sickle cell disease therapy Oxbryta. This September, a safety scare caused the company to pull Oxbryta from the ...